文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.

作者信息

Yang Na, Zhou Xi, Gong Yangmei, Deng Zhizhi

机构信息

The First Affiliated Hospital, Gynecology & Obstetrics and Reproductive Medical Center, Hengyang Medical School, University of South China, No. 69, Chuanshan Avenue, Shigu District, Hengyang, 421001, Hunan Province, China.

出版信息

BMC Cancer. 2025 Feb 19;25(1):294. doi: 10.1186/s12885-025-13461-0.

DOI:10.1186/s12885-025-13461-0
PMID:39972413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11837316/
Abstract

In this study, the influence of glycoproteomic changes, specifically MUC16, on NK cell-mediated immunotherapy response in ovarian cancer is explored. Analysis of glycoprotein data from the CPTAC database identified significant upregulation of MUC16 in ovarian cancer tissues, associated with tumor invasiveness and immune evasion. Experimental findings showed that MUC16 knockdown increased NK cell cytotoxicity, decreased invasiveness, and boosted NK cell activation, while MUC16 overexpression resulted in the opposite effects. In vivo experiments demonstrated that MUC16 knockdown suppressed tumor growth, enhanced NK cell infiltration, and bolstered NK cell activation, underscoring the potential of MUC16 as a target for novel immunotherapy approaches in ovarian cancer treatment.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/99614b4bbff2/12885_2025_13461_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/8af5df2859d8/12885_2025_13461_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/59bb5c030f1e/12885_2025_13461_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/985226e3565c/12885_2025_13461_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/e9997527d491/12885_2025_13461_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/35abb736283b/12885_2025_13461_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/99614b4bbff2/12885_2025_13461_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/8af5df2859d8/12885_2025_13461_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/59bb5c030f1e/12885_2025_13461_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/985226e3565c/12885_2025_13461_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/e9997527d491/12885_2025_13461_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/35abb736283b/12885_2025_13461_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9ac/11837316/99614b4bbff2/12885_2025_13461_Fig6_HTML.jpg

相似文献

[1]
The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.

BMC Cancer. 2025-2-19

[2]
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.

Mol Cancer. 2010-1-20

[3]
Circ_MUC16 attenuates the effects of Propofol to promote the aggressive behaviors of ovarian cancer by mediating the miR-1182/S100B signaling pathway.

BMC Anesthesiol. 2021-11-27

[4]
MUC16 suppresses human and murine innate immune responses.

Gynecol Oncol. 2019-1-6

[5]
Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.

Drug Deliv. 2018-11

[6]
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.

Oncoimmunology. 2022

[7]
Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.

Biol Chem. 2014-10

[8]
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.

PLoS One. 2015-5-12

[9]
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).

Immunology. 2007-11

[10]
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.

Sci Transl Med. 2019-6-19

引用本文的文献

[1]
Early-Stage Pancreatic Cancer Diagnosis: Serum Biomarkers and the Potential for Aptamer-Based Biosensors.

Molecules. 2025-4-30

本文引用的文献

[1]
Mendelian Randomization Applied to Neurology: Promises and Challenges.

Neurology. 2024-2-27

[2]
Mesenchymal stem cells overexpressing XIST induce macrophage M2 polarization and improve neural stem cell homeostatic microenvironment, alleviating spinal cord injury.

J Tissue Eng. 2024-1-10

[3]
A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.

Cancer Res Commun. 2024-1-31

[4]
Sarcosine dehydrogenase as an immune infiltration-associated biomarker for the prognosis of hepatocellular carcinoma.

J Cancer. 2024-1-1

[5]
Biomarkers of ocular allergy and dry eye disease.

Rom J Ophthalmol. 2023

[6]
Clinical and translational advances in ovarian cancer therapy.

Nat Cancer. 2023-9

[7]
MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.

J Ovarian Res. 2023-8-30

[8]
Interferon-ε is a tumour suppressor and restricts ovarian cancer.

Nature. 2023-8

[9]
Update value and clinical application of MUC16 (cancer antigen 125).

Expert Opin Ther Targets. 2023

[10]
Blood Plasma Small Non-Coding RNAs as Diagnostic Molecules for the Progesterone-Receptor-Negative Phenotype of Serous Ovarian Tumors.

Int J Mol Sci. 2023-7-30

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索